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Surface modification with polyethylene glycol (PEG) has been employed in the development 
of biomaterials to reduce unfavorable reactions. Unanticipated body reactions, however, have 
been reported, with activation of the complement system suggested as having involvement in 
these responses. In this study, we prepared a PEG-modified surface on a gold surface using a 
monolayer of α-mercaptoethyl-ω-methoxy-polyoxyethylene (HS-mPEG). We observed 
neither protein adsorption nor activation of the complement system on the PEG-modified 
surface just after preparation. After storage of the PEG-modified surface in a dessicator under 
ambient light for several days or following UV irradiation, reflection-adsorption (FTIR-RAS) 
and X-ray photo spectrometry both revealed deterioration of the PEG layer, which became a 
strong activator of the complement system through the alternative pathway.  
Keywords; 




1. Introduction  
Surface modification with polyethylene glycol (PEG) is one of the most promising 
strategies to prevent and/or reduce adsorption of proteins and the aftereffects of the 
interaction of body fluids with biomaterials [1,2]. PEG has also been used for pharmaceutical 
applications to shield antigenicity of proteinaceous drugs and to prolong the circulating half-
life of drug-loaded nanoparticles and liposomes [3-5]. However, unanticipated body reactions 
such as hypersensitivity caused by PEG-modified liposomes [6-9] and rapid clearance of 
PEG-modified liposomes from blood [10] have been reported. Activation of the complement 
system has been suggested as being associated with these body reactions [11]. The 
complement system, which plays important roles in the body’s defense system against 
pathogenic xenobiotics, is an enzyme cascade system that consists of approximately 30 fluid-
phase and cell-membrane bound proteins [12]. It is activated through three separate 
pathways: the classical pathway (CP), the lectin pathway(LP), and the alternative pathway 
(AP) (Scheme 1A). Understanding the interaction of complement proteins with the PEG-
modified surface may provide a basis for developing PEG-modified materials for biomedical 
and pharmaceutical use. 
In a previous study [13], we examined complement activation behaviors on PEG-
modified surfaces; however, there were uncertainties about the experimental setup. First, we 
used diluted (10%) normal human serum (NHS), and it has been reported that activation of 
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the alternative pathway may be diminished with use of diluted serum [14,15]. In addition, the 
PEG-modified surfaces were not sufficiently characterized. In the current study, we prepared 
a PEG-modified surface on a gold surface using a self-assembled monolayer of α-
mercaptoethyl-ω-methoxy-polyoxyethylene (HS-mPEG). We then carried out detailed 
surface analyses of PEG-modified surfaces using the reflection-adsorption method (FTIR-
RAS) and X-ray photo spectrometry (XPS) and examined activation of the complement 
system using undiluted NHS to obtain more detailed insight into the mechanisms of 
complement system activation by the PEG-modified surfaces. 
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2. Materials and methods 
2.1. Reagents and antibodies 
HS-mPEG (SUNBRIGHT ME-050SH, Mn = 5000, NOF Corporation, Tokyo, Japan) 
was used as provided. Barbital sodium, calcium chloride, magnesium chloride, and O,O'-
bis(2-aminoethyl)ethyleneglycol-N,N,N',N'-tetraacetic acid (EGTA) (all purchased from 
Nacalai Tesque, Inc., Kyoto, Japan) and ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA; 





 cations and inhibits all three activation pathways of the complement system. EGTA 
with abundant Mg
2+
 cation captures Ca
2+
 cation and thus inhibits classical and lectin 
pathways of the complement system. Ethanol (reagent grade, Nacalai Tesque) was 
deoxygenized with nitrogen gas bubbling before use. Water was purified with a MilliQ 
system (Millipore Co.). Rabbit anti-human C3b antiserum (RAHu/C3b) was purchased from 
Nordic Immunological Laboratories (Tilburg, The Netherlands) and its solution prepared and 
stored in accordance with supplier instructions. 
 
2.2. Preparation of NHS and buffers 
All participants enrolled in this research provided informed consent, which was 
approved and accepted by the ethics review board of the Institute for Frontier Medical 
Sciences, Kyoto University. Blood was donated from 10 healthy volunteers who had 
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consumed a meal at least 4 h before the donation. The preparation method for the NHS has 
been described elsewhere [13]. Briefly, the collected blood was kept at ambient temperature 
for 30 min and centrifuged at 4 °C. Supernatant was pooled and mixed and stored at -80 °C 
until use. Veronal buffer (VB) was prepared referring to a protocol of CH50 measurement 
[16]. To prevent complement activation completely, 10 µl of 0.5 M EDTA aqueous solution 
(pH 7.4) was added to 490 µl of NHS (final concentration of EDTA, 10 mM). To block the 
classical pathway of the complement system, 10 µl of a mixture of 0.5 M EGTA and 0.1 M 
MgCl2 aqueous solution (pH 7.4) was added to 490 µl of NHS (final concentration of EGTA, 
10 mM; Mg
2+
, 2 mM). 
 
2.3. Preparation self-assembled monolayer (SAM) of HS-mPEG 
Glass plates were coated with gold as previously reported [13,17]. The gold-coated 
glass plate was immersed in a 4 mM solution of HS-mPEG in a 1:6 mixture of Milli-Q water 
and ethanol at room temperature for at least 24 h to form the HS-mPEG–coated surface 
(Scheme 1B). Finally, the glass plate carrying a monolayer of HS-mPEG was sequentially 
washed with ethanol and Milli-Q water three times with each and then dried under a stream 
of dried nitrogen gas. The plate carrying a monolayer of HS-mPEG (naïve mPEG) was 
subjected to complement activation tests. The plates were stored in a desiccator under room 
light for a predetermined time to assess the effects of deterioration of the mPEG layer on 
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complement activation (R-mPEG). To observe more directly the effects of UV oxidation, 
surfaces carrying mPEG were UV irradiated at 20 cm from a 15-W germicidal lamp 
(Matsushita Electric Industrial Co., Ltd., Osaka, Japan) in air at room temperature for 60 min 
(UV-mPEG)[13](Scheme 1B). Plates carrying 11-mercaptoundecanol (Sigma-Aldrich Co., St. 
Louis, MO, USA) were formed as previously reported [17,18] and used as a positive control. 
 
2.4. Surface analyses of modified surfaces carrying mPEG 
Infrared (IR) adsorption spectra of sample surfaces were collected by the reflection-
adsorption method (FTIR-RAS) using a Spectrum One (Perkin-Elmer, USA) spectrometer 
equipped with a Refractor
TM
 (Harrick Sci. Co., NY, USA) in a chamber purged with dry 
nitrogen gas and a mercury-cadmium telluride detector cooled by liquid nitrogen. Gold-
coated glass plates with a gold layer of 49 nm thickness were used for FTIR-RAS analysis. 
Spectra were obtained using the p-polarized IR laser beam at an incident angle of 75 degrees 
for 128 scans at 4 cm
-1
 resolution from 4000 to 750 cm
-1
. 
Surfaces were also analyzed by using XPS. The XPS spectra of the surfaces were 
collected by an ESCA-850V (Shimadzu Co., Kyoto, Japan), with a magnesium target and an 
electric current through the filament of 30 mA at 8 kV. The pressure of the analysis chamber 
was less than 1×10
-5
 Pa. All spectra shown in the figures were corrected by reference to the 
peak of Au 4f7/2 to 83.8 eV.  
 6 
 
2.5. Total protein and C3b deposition observed by surface plasmon resonance (SPR)  
We used an SPR apparatus assembled in our laboratory [18]. Gold-coated glass plates 
with a gold layer of 49 nm thickness were used. Undiluted NHS or NHS supplemented with 
EDTA or EGTA was injected into a flow cell, and change in the SPR angle was monitored as 
a function of time for 90 min. After the NHS was washed out with VB, a solution of rabbit 
anti-human C3b antiserum diluted to 1% with VB was applied to detect C3b and C3b 
degraded products, and the change of the SPR angle was estimated to determine antibody 
binding on the surface. 
Protein layer thickness was calculated from the SPR angle shift using Fresnel fits for 
the system BK7/Cr/Au/SAM/protein/water [19,20]. Both refractive indices of SAM and 
protein layers were assumed to be 1.45 [19,20], and the density of the protein layer was 
assumed to be 1.0. From these values, the amounts of proteins adsorbed onto the surfaces 
could be estimated from the following simple relation [18]: 1.0 degree SPR angle shift (DA) 
→ 0.5 µg of protein on 1 cm2 of the surface.  
 
2.6. Release of the soluble form of the membrane attack complex, SC5b-9, and 
anaphylatoxins C5a and C3a 
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We used a lab-made incubation chamber to examine release of C3a-desArg, SC5b-9, 
and C5a-desArg when NHS samples were exposed to different surfaces. The chamber was 
composed of two glass plates carrying the same sample surfaces and a silicone gasket of 1 
mm thickness with a hole of 20 mm in diameter. After NHS samples were incubated in the 
chamber for 1.5 h at 37 °C, they were collected and EDTA was immediately added to a final 
concentration of 10 mM to stop further activation of the complement system. Commercial 
enzyme-linked immunosorbent assay (ELISA) kits (for C3a-desArg detection: BD OptEIA 
Human C3a ELISA, BD Biosciences Pharmingen, CA, USA; for C5a-desArg detection: BD 
OptEIA Human C5a ELISA, BD Biosciences Pharmingen, CA, USA; for the soluble form of 
membrane attack complex - SC5b-9: Quidel SC5b-9(TCC) EIA kit, Quidel Corp., CA, USA) 
were used to determine the fragments, C3a-desArg and C5a-desArg, and the complex, SC5b-
9, in the collected NHS samples. The measurement procedure was performed in accordance 
with supplier instructions. 
 
2.7. Statistical analysis 
Data from the experiments are expressed as the mean ± standard deviation. A one-way 
analysis of variance (ANOVA) was used to identify the statistical significance of the data. 
ANOVA was followed by post-hoc pair-wise t-tests adjusted using Holm’s method and 
employing R language environment ver. 2.9.1 [21]. 
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3. Results 
3.1. Analyses of mPEG surfaces 
FTIR adsorption spectra and XPS spectra were obtained to study HS-mPEG SAM 
formation and its deterioration during storage under ambient conditions and in a -20 °C 
freezer (F-mPEG). Fig. 1A shows the C-O-C stretch region of the IR spectra and Fig. 1B 
shows the C1s region of the XPS spectra for naïve mPEG, F-mPEG, R-mPEG, and UV-
mPEG. Signal intensities obtained from R-mPEG and UV-mPEG surfaces significantly 
decreased in the region of C-O-C stretch of the IR spectra. For XPS spectra, the intensity 
ratios of C1s over Au 4f signals also decreased with storage under the ambient conditions or 
treatment by UV irradiation. These results suggest that the mPEG layers became thinner by 
degradation of mPEG chains or that an mPEG surface became heterogeneous by removal of 
some part of the mPEG surface during storage and UV irradiation. Fig. 1 also includes an 
mPEG surface that was stored in a -20 °C freezer for 12 days (F-mPEG). The F-mPEG 
surfaces did not demonstrate such changes in either the FTIR adsorption spectra or XPS 
spectra. Therefore, the mPEG surface could be stored without damage in a -20 °C freezer for 
at least 12 days.  
 
3.2. Protein adsorption and C3b deposition onto mPEG-HS surfaces 
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When mPEG surfaces were exposed to NHS, we used SPR to follow protein adsorption 
and activation of the complement system. Fig. 2 shows SPR sensorgrams for the naïve mPEG, 
F-mPEG, and R-mPEG surfaces. Initially sharp increases in SPR angle shifts were the result 
of a larger refractive index of NHS than VB (Fig. 2A). For the cases of naïve mPEG and/or 
F-mPEG surfaces, no additional increase in SPR angles was observed during exposure to 
NHS. When NHS was washed out by infusion of VB, the SPR signals rapidly decreased to 
the low pre-exposure levels. The SPR angle shifts indicate that small amounts (0.04 µg/cm
2
) 
of proteins adsorbed onto naïve mPEG and F-mPEG. On the other hand, the SPR angle shift 
continuously increased during exposure to NHS on the R-mPEG surface. After the surface 
was exposed to NHS for 90 min, NHS was washed out by infusion of VB. A large shift in 
SPR angle (1600 mDA) was still observed. The amount of adsorbed proteins estimated from 
the SPR angle shift was 0.8 µg/cm
2
.  
When the complement system is activated through any of the three pathways, C3b is 
immobilized on surfaces, as Scheme 1A illustrates. After NHS was washed out, a solution of 
anti-C3b antiserum was applied to examine the existence of C3b and C3b degraded products 
in the protein layers formed on the mPEG surfaces (Fig. 2B). The SPR angles gradually 
increased with time. Only 0.17 and 0.19 µg/cm
2
 of anti-C3b antibody were immobilized on 
the mPEG and F-mPEG surfaces, respectively. On the other hand, a much larger amount of 
anti-C3b antibody (0.95 µg/cm
2
) was bound on the protein adsorbed layer formed on the R-
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mPEG surface. These results indicate that the naïve mPEG surface deteriorated during 
storage under ambient conditions and acquired the ability to activate the complement system.  
Fig. 2 also includes behaviors of protein adsorption and anti-C3b antibody deposition 
on the UV-mPEG surface. They were the same on the UV-mPEG surfaces as on the R-mPEG. 
Irradiation with UV light could accelerate the deterioration of the naïve mPEG surface, and 
the mPEG layer gained the ability to activate the complement system. 
 
3.3. Release of C3a, SC5b-9, and C5a  
C3 is cleaved into C3a and C3b in the contact activation of the complement system on 
artificial materials. The C3 convertase, C3bBb, which forms on artificial materials, cleaves 
the α-chain of C3, generating C3a and C3b, and then the smaller 9-kDa anaphylatoxin C3a is 
released into the fluid phase and rapidly cleaved to form C3a-desArg. Thus, the presence of 
C3a/C3a-desArg in the fluid phase indicates activation of the complement system. Fig. 3A 
shows the results for C3a/C3a-desArg levels in NHS samples applied to naïve mPEG, R-
mPEG, and UV-mPEG. Amounts of C3a-desArg released into NHS samples on the R-mPEG 
and UV-mPEG surfaces were significantly greater than those on naïve mPEG surfaces. 
A terminal complement complex, C5b-9, is generated by the assembly of C5 though C9 
as a consequence of activation of the complement system. In the absence of a target cell 
membrane (that is, activation on artificial materials), it binds to regulatory proteins, like the S 
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protein, and is released to serum as a non-lytic SC5b-9 complex. When the complement 
system is activated on mPEG surfaces, we expect release of SC5b-9 into serum. Fig. 3B 
summarizes the released amounts of SC5b-9 identified when NHS samples were incubated 
with naïve mPEG, R-mPEG, and UV-mPEG. Although a small amount of SC5b-9 was found 
when naïve mPEG surfaces were examined, large amounts of SC5b-9 were observed in NHS 
samples exposed to the R-mPEG and UV-mPEG surfaces. Those amounts were much larger 
than those observed in NHS samples exposed to OH-SAM, which has been reported to be a 
strong complement activator [18]. 
The C5 convertases (C4b2a3b : the classical and the lectin pathways, C3bBb : the 
alternative pathway) cleaves the α-chain of C5, generating C5a and C5b, and then the smaller 
11-kDa anaphylatoxin C5a is released into the fluid phase and rapidly cleaved to form C5a-
desArg. Thus, the presence of C5a/C5a-desArg in the fluid phase also indicates activation of 
the complement system. The generated amounts of C5a-desArg were also determined, 
showing a tendency that was almost the same as that for SC5b-9 measurements (Fig. 3C). 
 
3.4. Activation pathway 
Whereas addition of EDTA to NHS inhibited all three activation pathways, addition of 
EGTA-Mg
2+
 can inhibit the classical and lectin pathways, but not the alternative pathway. 
Fig. 4 and Fig. 5 show effects of addition of EDTA and EGTA-Mg
2+
 on the complement 
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activation. When an R-mPEG and UV-mPEG surface was exposed to NHS supplemented 
with 10 mM EDTA, the amounts of adsorbed serum proteins and anti-C3b antibody bound 
were greatly reduced. Practically no protein adsorbed onto the surface in the presence of 
EDTA. In NHS samples supplemented with 10 mM EGTA-Mg
2+
, protein adsorption was 
retarded but gradually increased at 20 min after exposure. Using anti-C3b antibody, we 
detected a large amount of C3b/C3bBb and C3b degraded products in the protein-adsorbed 
layer. These results indicate that the complement system was activated through the alternative 
pathway on the R-mPEG and UV-mPEG surfaces.  
 
4. Discussion 
Although PEG has been widely used for preparation of biomedical devices and dug 
carriers to reduce interaction of artificial materials with proteins and cells, unanticipated body 
reactions such as hypersensitivity reactions caused by PEG-modified surfaces have been 
reported [6-9]. Body reactions against PEG-modified surfaces should be carefully examined.  
In our previous study [13], naïve mPEG, and R-mPEG and UV-mPEG surfaces were exposed 
to 10% diluted NHS and then anti-C3b antiserum was applied to see immobilization of C3b 
on these surfaces. A large amount of anti-C3b antibody was found on R-mPEG and UV-
mPEG surfaces, but not naïve mPEG. These results suggest that naïve mPEG is not an 
activator of the complement system, but R-mPEG and UV-mPEG surfaces are strong 
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activators. We need more relevant supporting data to conclude it and to identify activation 
pathways. In this study, complement activation by the latter two surfaces was further 
confirmed by releases of C3a-desArg, C5a-desArg and SC5b-9 into liquid phase NHS. Even 
with blocking of the classical and lectin pathways by the addition of EGTA-Mg
2+
 to NHS, R-
mPEG and UV-mPEG surfaces can activate the complement system. We concluded from all 
of these data that R- and UV-mPEG surfaces activate the complement system through the 
alternative pathway. 
 In our previous study [13], we also examined a surface carrying tri(ethylene glycol)-
terminated alkanethiol (HS-TEGOH) as an activator of the complement system. When the 
classical pathway was blocked with EGTA-Mg
2+
, deposition of proteins, including C3b, on it 
was delayed from 0 min and 40 min by addition of EGTA-Mg
2+
 to 10% NHS, respectively. 
Several groups have reported that a protein layer containing IgG formed on artificial 
materials starts the activation of the complement system through the classical pathway and 
then an amplification loop of the alternative pathway follows [22-25]. Complement activation 
should be carefully examined under more physiologically relevant conditions. We expected 
that amounts of proteins (including IgG and IgM) deposited on naïve mPEG surface increase 
with increasing serum concentration and thus it becomes an activator. No proteins adsorption, 
however, was detected on naïve mPEG surface when it was exposed to undiluted NHS. It 
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indicates that naïve mPEG neither activates complement system through the classical nor 
alternative pathway even in undiluted NHS.  
Kiwada’s group reported that PEG-modified liposomes activate the complement system, 
resulting in opsonization of liposomes [26-28]. When the spleen of a recipient was removed, 
no opsonization was observed [28]. From this fact, they inferred that anti-PEG IgM [26,27] 
secreted from the spleen [28] activated the complement system on PEG liposomes through 
the classical pathways. Our serum donors had not been exposed to PEG-modified substances; 
thus, it is difficult to predict whether they carried anti-PEG IgM or IgG antibodies.  
R-mPEG and UV-mPEG surfaces showed a 64% and 43% decrease in C-O-C peak area 
of IR spectra and a 43% and 36% decrease in C/Au ratios of XPS spectra, respectively. These 
decreases might arise from (1) the heterogeneous removal of whole HS-mPEG chains from 
gold surfaces or (2) removal of low molecular weight substances produced by degradation of 
PEG chains on the specimens. We examined protein adsorption onto a bear Au surface, a 
large amount of proteins, 0.49 g/cm2 and 0.89 g/cm2, was found on it when it was exposed 
to NHS and 1% -grobulin/VB solution, respectively. In the former situation, proteins should 
be adsorbed onto the bare area of the surface with surface exposure to NHS supplemented 
with EDTA. As Fig. 4 shows, however, we observed no protein adsorption. This finding 
indicates that the latter situation is more likely.  
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It has been reported that PEG chains are degraded through mechanical shocks, heating, 
and irradiation with light [29,30]. Mkhatresh et al. [29] proposed a degradation mechanism of 
PEG chains under light irradiation as follows:  
The resulting fragments of PEG chains carry OH groups at the chain ends. The 
nucleophilic OH groups have been reported to strongly activate the complement system 
through the alternative pathway. As mentioned previously, complement activation on the 
mPEG surfaces robustly correlates with decreased PEG chain length on the surfaces. These 
facts indicate that the PEG layer easily deteriorated, resulting in formation of a surface 
carrying nucleophilic OH groups, and thus gained the ability to activate the complement 
system through the alternative pathway after storage in a dessicator under ambient light for 
several days or after UV irradiation. 
 
Conclusion 
O   CH2 CH2 O O   CH    CH2 O
OOH
O   C   H
O




A PEG-modified surface strongly activates the complement system through the 
alternative pathway after its storage under ambient conditions for several days. PEG-modified 
artificial materials, proteins, and liposomes should be carefully stored. 
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Scheme 1. Schematic illustration of the complement activation pathways (A) and a surface 
modified with methoxy-capped PEG (B). Reprinted from Biomaterials 29(5), Arima Y. et al., 
"Complement activation on surfaces modified with ethylene glycol units", p. 552, Copyright 
(2008), with permission from Elsevier. 
 
Fig. 1. Analyses of HS-mPEG–carrying surfaces. FTIR-RAS spectra and peak areas of C-O-
C stretch region (A); error bars represent ± SD (n=8). XPS spectra of carbon atoms and 
intensity ratios of C1s over Au 4f signals of HS-mPEG carrying surfaces (B); error bars 
represent ± SD (n=9). ( ): naïve HS-mPEG, ( ): F-mPEG, ( ): R-
mPEG, ( ): UV-mPEG surfaces. 
 
Fig. 2. SPR sensorgrams. During exposure of undiluted normal human serum (NHS) to HS-
mPEG surfaces (A). Sequential exposure of 1% anti-C3b antiserum to the surfaces (B). 
( ): naïve HS-mPEG, ( ): F-mPEG, ( ): R-mPEG, ( ): UV-
mPEG surfaces. DA: degrees of angle. 
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Fig. 3. Release of C3a-desArg, SC5b-9, and C5a-desArg into NHS. Undiluted serum was 
exposed to CH3-, OH-SAM, and naïve mPEG, R-mPEG and UV-mPEG surfaces. CH3- and 
OH-SAM were used as negative- and positive-controlled surfaces, respectively, for 
complement activation, and zymosan was used to fully activate complement. Experiments 
were repeated 3 times for each surface. C3a-desArg (A): Amounts of C3a-desArg in naïve 
undiluted NHS and fully activated by incubation with zymosan were 3.3 ± 0.6 µg/cm
3
 (n=3) 
and 56.2 ± 4.5 µg/cm
3
 (n=3), respectively; error bars represent ± SD. SC5b-9 (B): amounts of 
SC5b-9 in naïve undiluted NHS and fully activated by incubation with zymosan were 0.3 ± 
0.03 µg/cm
3
 (n=3) and 310 ± 34 µg/cm
3
 (n=3), respectively; error bars represent ± SD. C5a-
desArg (C): amounts of C5a-desArg in naïve undiluted NHS and fully activated by 
incubation with zymosan were 0.010 ± 0.007 µg/cm
3
 (n=3) and 3.0 ± 0.2 µg/cm
3
 (n=3), 
respectively; error bars represent ± SD.  
 
Fig 4. Effect of EDTA and EGTA added to NHS on complement activation on R-mPEG 
surfaces. SPR sensorgrams during exposure of NHS (A), and sequential exposure of 1% anti-
C3b antiserum to the surfaces (B). ( ): NHS (same data in Fig. 2), ( ): NHS 
supplemented with 10 mM EDTA, ( ): NHS supplemented with 10 mM EGTA (with 
2 mM Mg
2+
). DA: degrees of angle. 
 
 3 
Fig 5. Effect of EDTA and EGTA added to NHS on complement activation on UV-mPEG 
surfaces. SPR sensorgrams during exposure of NHS (A), and sequential exposure of 1% anti-
C3b antiserum to the surfaces (B). ( ): NHS (same data in Fig. 2), ( ): NHS 
supplemented with 10 mM EDTA, ( ): NHS supplemented with 10 mM EGTA (with 
2 mM Mg
2+
). DA: degrees of angle. 
OH
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mPEG surfaces examined after preparation procedure : “naive mPEG"
mPEG surfaces stored in -20 C freezer for 12 days : “F-mPEG"
mPEG surfaces stored in a dessicator under room light : “R-mPEG"
mPEG surfaces irradiated with UV light for 60 min. : "UV-mPEG"
mPEG surfaces 
Toda M. et. al, Scheme 1B
(B)




























































Toda M. et. al, Fig. 1A









































Toda M. et. al, Fig. 1B




















































































































































































































Toda M. et. al, Fig. 3C
(C)


















































Toda M. et. al, Fig. 4



















































Toda M. et. al, Fig. 5
